Legal & General Group
LUCD icon

Legal & General Group’s Lucid Diagnostics LUCD Stock Holding History

Legal & General Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.26K Sell
6,315
-840
-12% -$1.07K ﹤0.01% 3243
2025
Q4 		$7.8K Hold
7,155
– – ﹤0.01% 3296
2025
Q3 		$7.23K Hold
7,155
– – ﹤0.01% 3337
2025
Q2 		$8.23K Buy
+7,155
New +$9.24K ﹤0.01% 3334
2022
Q2 		– Sell
-500
Closed -$2K – 3599
2022
Q1 		$2K Hold
500
– – ﹤0.01% 3550
2021
Q4 		$3K Buy
+500
New +$4.06K ﹤0.01% 3562

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Legal & General Group's LUCD Position: Q1 2026 in Review

Legal & General Group reduced its Lucid Diagnostics (LUCD) stake by 12% in Q1 2026, selling an estimated $1.07K and leaving 6,315 shares worth $7.26K. The position accounts for ﹤0.01% of the portfolio, ranked #3243.

Legal & General Group first reported a position in LUCD in Q4 2021 and has held it in 6 quarters since. The position peaked at $8.23K in Q2 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Legal & General Group held 6,315 shares of Lucid Diagnostics worth $7.26K as of Q1 2026.
  • Legal & General Group sold 840 Lucid Diagnostics shares in Q1 2026, an estimated $1.07K.
  • Lucid Diagnostics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3243 holding.
  • Legal & General Group first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 6 quarters since.
  • Legal & General Group's Lucid Diagnostics position peaked at $8.23K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.